SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma launches Cinacalcet Hydrochloride Tablets

11 Jul 2019 Evaluate

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1393.50 25.80 (1.89%)
21-Apr-2026 14:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1671.20
Dr. Reddys Lab 1220.40
Cipla 1233.30
Zydus Lifesciences 930.70
Lupin 2314.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×